• Something wrong with this record ?

Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management

F. Bridoux, V. Javaugue, S. Bender, F. Leroy, P. Aucouturier, C. Debiais-Delpech, JM. Goujon, N. Quellard, A. Bonaud, M. Clavel, P. Trouillas, F. Di Meo, JM. Gombert, JP. Fermand, A. Jaccard, M. Cogné, G. Touchard, C. Sirac,

. 2017 ; 91 (2) : 423-434. [pub] 20161020

Language English Country United States

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18016974

Randall-type heavy chain deposition disease (HCDD) is a rare disorder characterized by tissue deposition of a truncated monoclonal immunoglobulin heavy chain lacking the first constant domain. Pathophysiological mechanisms are unclear and management remains to be defined. Here we retrospectively studied 15 patients with biopsy-proven HCDD of whom 14 presented with stage 3 or higher chronic kidney disease, with nephrotic syndrome in 9. Renal lesions were characterized by nodular glomerulosclerosis, with linear peritubular and glomerular deposits of γ-heavy chain in 12 patients or α-heavy chain in 3 patients, without concurrent light chain staining. Only 2 patients had symptomatic myeloma. By serum protein electrophoresis/immunofixation, 13 patients had detectable monoclonal gammopathy. However, none of these techniques allowed detection of the nephrotoxic truncated heavy chain, which was achieved by immunoblot and/or bone marrow heavy chain sequencing in 14 of 15 patients. Serum-free kappa to lambda light chain ratio was abnormal in 11 of 11 patients so examined. Immunofluorescence studies of bone marrow plasma cells showed coexpression of the pathogenic heavy chain with light chain matching the abnormal serum-free light chain in all 3 tested patients. Heavy chain sequencing showed first constant domain deletion in 11 of 11 patients, with high isoelectric point values of the variable domain in 10 of 11 patients. All patients received chemotherapy, including bortezomib in 10 cases. Renal parameters improved in 11 patients who achieved a hematological response, as assessed by normalization of the free light chain ratio in 8 cases. Tissue deposition in HCDD relates to physicochemical peculiarities of both variable and constant heavy chain domains. Early diagnosis and treatment with bortezomib-based combinations appear important to preserve renal prognosis. Thus, monitoring of serum-free light chain is an indirect but useful method to evaluate the hematological response.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016974
003      
CZ-PrNML
005      
20180517141141.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.kint.2016.09.004 $2 doi
035    __
$a (PubMed)27773425
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bridoux, Frank $u Department of Nephrology, University Hospital of Poitiers, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Poitiers, France; Department of Immunology, National Center for Scientific Research, Joint Research Unit 7276, University of Limoges, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Limoges, France. Electronic address: Franck.BRIDOUX@chu-poitiers.fr.
245    10
$a Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management / $c F. Bridoux, V. Javaugue, S. Bender, F. Leroy, P. Aucouturier, C. Debiais-Delpech, JM. Goujon, N. Quellard, A. Bonaud, M. Clavel, P. Trouillas, F. Di Meo, JM. Gombert, JP. Fermand, A. Jaccard, M. Cogné, G. Touchard, C. Sirac,
520    9_
$a Randall-type heavy chain deposition disease (HCDD) is a rare disorder characterized by tissue deposition of a truncated monoclonal immunoglobulin heavy chain lacking the first constant domain. Pathophysiological mechanisms are unclear and management remains to be defined. Here we retrospectively studied 15 patients with biopsy-proven HCDD of whom 14 presented with stage 3 or higher chronic kidney disease, with nephrotic syndrome in 9. Renal lesions were characterized by nodular glomerulosclerosis, with linear peritubular and glomerular deposits of γ-heavy chain in 12 patients or α-heavy chain in 3 patients, without concurrent light chain staining. Only 2 patients had symptomatic myeloma. By serum protein electrophoresis/immunofixation, 13 patients had detectable monoclonal gammopathy. However, none of these techniques allowed detection of the nephrotoxic truncated heavy chain, which was achieved by immunoblot and/or bone marrow heavy chain sequencing in 14 of 15 patients. Serum-free kappa to lambda light chain ratio was abnormal in 11 of 11 patients so examined. Immunofluorescence studies of bone marrow plasma cells showed coexpression of the pathogenic heavy chain with light chain matching the abnormal serum-free light chain in all 3 tested patients. Heavy chain sequencing showed first constant domain deletion in 11 of 11 patients, with high isoelectric point values of the variable domain in 10 of 11 patients. All patients received chemotherapy, including bortezomib in 10 cases. Renal parameters improved in 11 patients who achieved a hematological response, as assessed by normalization of the free light chain ratio in 8 cases. Tissue deposition in HCDD relates to physicochemical peculiarities of both variable and constant heavy chain domains. Early diagnosis and treatment with bortezomib-based combinations appear important to preserve renal prognosis. Thus, monitoring of serum-free light chain is an indirect but useful method to evaluate the hematological response.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biopsie $7 D001706
650    _2
$a bortezomib $x terapeutické užití $7 D000069286
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluorescenční protilátková technika $7 D005455
650    _2
$a Francie $7 D005602
650    _2
$a glomerulonefritida $x farmakoterapie $x imunologie $x patologie $7 D005921
650    _2
$a nemoc z těžkých řetězců $x farmakoterapie $x genetika $x imunologie $x patologie $7 D006362
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobuliny - alfa-řetězce $x analýza $7 D007137
650    _2
$a imunoglobuliny - gama-řetězce $x analýza $x genetika $7 D007142
650    _2
$a imunoglobuliny - kappa-řetězce $x analýza $7 D007145
650    _2
$a imunoglobuliny - lambda-řetězce $x analýza $7 D007146
650    _2
$a ledviny $x účinky léků $x imunologie $x patologie $7 D007668
650    _2
$a nemoci ledvin $x farmakoterapie $x imunologie $x patologie $7 D007674
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nefrotický syndrom $x farmakoterapie $x imunologie $x patologie $7 D009404
650    _2
$a paraproteinemie $x farmakoterapie $x imunologie $7 D010265
650    _2
$a polymerázová řetězová reakce $7 D016133
650    _2
$a chronická renální insuficience $x farmakoterapie $x imunologie $x patologie $7 D051436
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Javaugue, Vincent $u Department of Nephrology, University Hospital of Poitiers, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Poitiers, France.
700    1_
$a Bender, Sébastien $u Department of Immunology, National Center for Scientific Research, Joint Research Unit 7276, University of Limoges, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Limoges, France.
700    1_
$a Leroy, Fannie $u Department of Nephrology, University Hospital of Poitiers, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Poitiers, France.
700    1_
$a Aucouturier, Pierre $u Department of Immunology, Inserm UMRS 938, Saint Antoine Hospital; Université Pierre et Marie Curie - Paris6, Paris, France.
700    1_
$a Debiais-Delpech, Céline $u Department of Pathology and Ultrastructural Pathology, University Hospital of Poitiers, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Poitiers, France.
700    1_
$a Goujon, Jean-Michel $u Department of Pathology and Ultrastructural Pathology, University Hospital of Poitiers, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Poitiers, France.
700    1_
$a Quellard, Nathalie $u Department of Pathology and Ultrastructural Pathology, University Hospital of Poitiers, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Poitiers, France.
700    1_
$a Bonaud, Amélie $u Department of Immunology, National Center for Scientific Research, Joint Research Unit 7276, University of Limoges, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Limoges, France.
700    1_
$a Clavel, Marie $u Department of Immunology, National Center for Scientific Research, Joint Research Unit 7276, University of Limoges, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Limoges, France.
700    1_
$a Trouillas, Patrick $u INSERM UMR 850, University of Limoges, School of Pharmacy, Limoges, France; Regional Centre of Advanced Technologies and Materials, Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic.
700    1_
$a Di Meo, Florent $u INSERM UMR 850, University of Limoges, School of Pharmacy, Limoges, France.
700    1_
$a Gombert, Jean-Marc $u Department of Immunology, University Hospital of Poitiers, Poitiers, France.
700    1_
$a Fermand, Jean-Paul $u Department of Hematology and Clinical Immunology, Saint Louis University Hospital, Paris, France.
700    1_
$a Jaccard, Arnaud $u Department of Hematology, University Hospital of Limoges, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Limoges, France.
700    1_
$a Cogné, Michel $u Department of Immunology, National Center for Scientific Research, Joint Research Unit 7276, University of Limoges, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Limoges, France.
700    1_
$a Touchard, Guy $u Department of Nephrology, University Hospital of Poitiers, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Poitiers, France.
700    1_
$a Sirac, Christophe $u Department of Immunology, National Center for Scientific Research, Joint Research Unit 7276, University of Limoges, Centre de référence de l'amylose AL et des autres maladies par dépôts d'immunoglobuline monoclonale, Limoges, France.
773    0_
$w MED00010141 $t Kidney international $x 1523-1755 $g Roč. 91, č. 2 (2017), s. 423-434
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27773425 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180517141318 $b ABA008
999    __
$a ok $b bmc $g 1300598 $s 1013814
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 91 $c 2 $d 423-434 $e 20161020 $i 1523-1755 $m Kidney international $n Kidney Int $x MED00010141
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options